Atrion (NASDAQ:ATRI) Sees Large Volume Increase

Atrion Co. (NASDAQ:ATRI) saw an uptick in trading volume on Tuesday . 11,008 shares traded hands during trading, a decline of 36% from the previous session’s volume of 17,223 shares.The stock last traded at $413.00 and had previously closed at $399.83.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Atrion from a “hold” rating to a “sell” rating in a report on Monday.

Atrion Stock Up 4.7 %

The business’s fifty day moving average is $402.59 and its two-hundred day moving average is $364.60. The stock has a market capitalization of $746.57 million, a PE ratio of 38.46 and a beta of 0.60.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share (EPS) for the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%. The company had revenue of $43.58 million during the quarter.

Atrion Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 15th were paid a $2.20 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $8.80 annualized dividend and a yield of 2.07%. Atrion’s dividend payout ratio (DPR) is presently 79.78%.

Hedge Funds Weigh In On Atrion

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATRI. Penn Mutual Asset Management LLC purchased a new position in Atrion in the fourth quarter valued at about $1,949,000. Citizens Financial Group Inc. RI purchased a new stake in shares of Atrion during the fourth quarter worth about $1,114,000. Boston Trust Walden Corp grew its stake in shares of Atrion by 4.8% during the fourth quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock worth $13,292,000 after acquiring an additional 1,609 shares during the last quarter. Exchange Traded Concepts LLC purchased a new stake in shares of Atrion during the third quarter worth about $333,000. Finally, Jump Financial LLC purchased a new stake in shares of Atrion during the fourth quarter worth about $234,000. Hedge funds and other institutional investors own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.